Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
CorrectionCorrection

Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program

Atul Deodhar, Denis Poddubnyy, Proton Rahman, Jeorg Ermann, Tetsuya Tomita, Rebeca Bolce, Soyi Liu Leage, Andris Kronbergs, Caroline Johnson, Joana Araújo, Ann Leung and Désirée van der Heijde
The Journal of Rheumatology January 2024, 51 (1) 108; DOI: https://doi.org/10.3899/jrheum.221022.C2
Atul Deodhar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis Poddubnyy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Proton Rahman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeorg Ermann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tetsuya Tomita
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebeca Bolce
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soyi Liu Leage
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andris Kronbergs
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joana Araújo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann Leung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Désirée van der Heijde
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

J Rheumatol 2023; doi:10.3899/jrheum.221022

The following text in the Results section of the originally published manuscript contained incorrect values: “Of the 173 patients who had a previous history of anterior uveitis, 41 patients had an episode of flare (IR 2.0 per 100 PYs), whereas 17 patients were new onset (0.8 per 100 PYs).”

This has been corrected to: “Of the 173 patients who had a previous history of anterior uveitis, 41 patients had an episode of flare (IR 10.7 per 100 PYs), whereas, of the 755 patients with no anterior uveitis, 17 patients were new onset (1.0 per 100 PYs).”

  • Copyright © 2024 by the Journal of Rheumatology
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 51, Issue 1
1 Jan 2024
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program
Atul Deodhar, Denis Poddubnyy, Proton Rahman, Jeorg Ermann, Tetsuya Tomita, Rebeca Bolce, Soyi Liu Leage, Andris Kronbergs, Caroline Johnson, Joana Araújo, Ann Leung, Désirée van der Heijde
The Journal of Rheumatology Jan 2024, 51 (1) 108; DOI: 10.3899/jrheum.221022.C2

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program
Atul Deodhar, Denis Poddubnyy, Proton Rahman, Jeorg Ermann, Tetsuya Tomita, Rebeca Bolce, Soyi Liu Leage, Andris Kronbergs, Caroline Johnson, Joana Araújo, Ann Leung, Désirée van der Heijde
The Journal of Rheumatology Jan 2024, 51 (1) 108; DOI: 10.3899/jrheum.221022.C2
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Epidemiology of Antisynthetase Syndrome and Risk of Malignancy in a Population-Based Cohort (1998-2019)
  • Conducting a High-Quality Systematic Review
  • Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study
Show more Correction

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire